Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ARV-6723

Other · developed by Arvinas

Phase 1/2 Most advanced trial

ARVN Developer

1 Registered trials

What is ARV-6723?

ARV-6723 is an investigational drug studied in Advanced Solid Tumor.

At a glance

Drug type: Other
Therapy area: Neurology
Developer: Arvinas Inc. (ARVN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07749586	Phase 1/2	Advanced Solid Tumor	Recruiting	ARVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor

More from Arvinas

ARV-806 Phase 1/2 Bavdegalutamide Phase 1/2 Zaloblideg Phase 1

Sources

ClinicalTrials.gov NCT07749586

Updated Oct 3, 2026. Something wrong or missing? Report it on the ARVN page.

Follow ARVN, the company behind ARV-6723

See ARVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARVN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z